![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
IN BRIEF: Arix Bioscience Investee Plans LB-001 Trial After US FDA Ok
IN BRIEF: Arix Bioscience Investee Plans LB-001 Trial After US FDA Ok
Read moreTue, 10th Mar 2020 11:49
IN BRIEF: Arix Bioscience Investee Plans LB-001 Trial After US FDA Ok
Read moreIN BRIEF: Arix Bioscience Notes Positive Data From Amplyx's Study
Read moreIN BRIEF: Arix's Atox To Submit Reltecimod Drug Application To US FDA
Read moreIN BRIEF: Arix's VelosBio Pockets USD137 Million In Fundraise
Read moreUK TRADING UPDATE SUMMARY: Feedback And Tissue Regenix Secure CE Marks
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read more(Sharecast News) - Venture capital company Arix Bioscience noted on Wednesday that its portfolio company, Amplyx Pharmaceuticals, has closed a $53m (£43.22m) series C extension.
Read moreArix Bioscience Notes First Patient Dosed In Harpoon's HPN217 Trial
Read moreSyncona, Arix Note US FDA Acceptance Of Autolus Drug Application
Read moreUK EXECUTIVE CHANGE SUMMARY: Two Co-Founders Leave Arix Bioscience
Read moreArix Biosciences Invests Further Into Imara Following US IPO Pricing
Read moreArix Bioscience Net Asset Value Declines In 2019 Amid Challenges
Read moreArix Bioscience Investee US IPO Price Set At USD16 To USD18 Per Share
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read more